International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(16), P. 9272 - 9272
Published: Aug. 17, 2022
This
review
is
devoted
to
changes
in
the
post-transcriptional
maturation
of
RNA
human
glioblastoma
cells,
which
leads
disruption
normal
course
apoptosis
them.
The
thoroughly
highlights
latest
information
on
both
modifications
certain
regulatory
RNAs,
associated
with
process
apoptosis,
presents
data
features
and
shows
relationship
between
RNAs
tumor
cells.
In
conclusion,
potential
target
candidates
are
presented
that
necessary
for
development
new
drugs
treatment
glioblastoma.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(5), P. 932 - 932
Published: April 23, 2024
Long
noncoding
RNAs
(lncRNAs)
are
RNA
molecules
of
200
nucleotides
or
more
in
length
that
not
translated
into
proteins.
Their
expression
is
tissue-specific,
with
the
vast
majority
involved
regulation
cellular
processes
and
functions.
Many
human
diseases,
including
cancer,
have
been
shown
to
be
associated
deregulated
lncRNAs,
rendering
them
potential
therapeutic
targets
biomarkers
for
differential
diagnosis.
The
lncRNAs
nervous
system
varies
different
cell
types,
implicated
mechanisms
neurons
glia,
effects
on
development
functioning
brain.
Reports
also
a
link
between
changes
lncRNA
etiopathogenesis
brain
neoplasia,
glioblastoma
multiforme
(GBM).
GBM
an
aggressive
variant
cancer
unfavourable
prognosis
median
survival
14-16
months.
It
considered
brain-specific
disease
highly
invasive
malignant
cells
spreading
throughout
neural
tissue,
impeding
complete
resection,
leading
post-surgery
recurrences,
which
prime
cause
mortality.
early
diagnosis
could
improve
treatment
extend
survival,
profiling
biological
fluids
promising
detection
neoplastic
at
their
initial
stages
effective
interventions.
This
review
presents
systematic
overview
GBM-associated
deregulation
focus
fingerprints
patients'
blood.
Journal of Personalized Medicine,
Journal Year:
2021,
Volume and Issue:
11(4), P. 258 - 258
Published: April 1, 2021
Glioblastoma
is
the
most
common
malignant
brain
tumor
in
adults.
The
current
management
relies
on
surgical
resection
and
adjuvant
radiotherapy
chemotherapy.
Despite
advances
our
understanding
of
glioblastoma
onset,
we
are
still
faced
with
an
increased
incidence,
altered
quality
life
a
poor
prognosis,
its
relapse
median
overall
survival
15
months.
For
past
few
years,
physiopathology
has
experienced
exponential
acceleration
yielded
significant
insights
new
treatments
perspectives.
In
this
review,
through
original
R-based
literature
analysis,
summarize
clinical
presentation,
standards
care
outcomes
patients
diagnosed
glioblastoma.
We
also
present
recent
perspectives
regarding
pathophysiological
bases
as
well
therapeutic
approaches
such
cancer
vaccination
personalized
treatments.
Bioengineered,
Journal Year:
2022,
Volume and Issue:
13(5), P. 11440 - 11455
Published: May 2, 2022
Glioblastoma
multiforme
(GBM)
is
a
malignant
cancer
with
severely
poor
survival,
and
the
cells
continue
to
thrive
during
hypoxia
toxic
stress
through
autophagy.
To
validate
oncogenic
role
of
long
noncoding
RNA
H19
in
GBM
progression
examine
whether
autophagy
and/or
miR-491-5p
participate
process.
The
expression
autophagy-related
genes
healthy
control
tissues
was
assessed
via
quantitative
polymerase
chain
reaction.
In
addition,
cell
viability,
proliferation,
apoptosis
were
respectively
determined
counting
kit-8
assay,
clone
formation
flow
cytometry,
western
blotting
green
fluorescent
protein-microtubule-associated
protein
1
light
3
alpha
fluorescence
analysis
Cancers,
Journal Year:
2021,
Volume and Issue:
13(7), P. 1604 - 1604
Published: March 31, 2021
Transcription
occurs
across
more
than
70%
of
the
human
genome
and
half
currently
annotated
genes
produce
functional
noncoding
RNAs.
Of
these
transcripts,
majority-long,
RNAs
(lncRNAs)-are
greater
200
nucleotides
in
length
are
necessary
for
various
roles
cell.
It
is
increasingly
appreciated
that
lncRNAs
relevant
both
health
disease
states,
with
brain
expressing
largest
number
compared
to
other
organs.
Glioblastoma
(GBM)
an
aggressive,
fatal
tumor
demonstrates
remarkable
intratumoral
heterogeneity,
which
has
made
development
effective
therapies
challenging.
The
cooperation
between
genetic
epigenetic
alterations
drives
rapid
adaptation
allows
therapeutic
evasion
recurrence.
Given
large
repertoire
normal
tissue
well-described
molecular
cellular
processes,
transcripts
important
consider
context
GBM
heterogeneity
treatment
resistance.
Herein,
we
review
general
mechanisms
biological
lncRNAs,
a
focus
on
GBM,
as
well
RNA-based
therapeutics
development.
Biomedicines,
Journal Year:
2022,
Volume and Issue:
10(8), P. 2031 - 2031
Published: Aug. 20, 2022
For
decades,
research
in
cancer
biology
has
been
focused
on
the
protein-coding
fraction
of
human
genome.
However,
with
discovery
non-coding
RNAs
(ncRNAs),
it
become
known
that
these
entities
not
only
function
numerous
fundamental
life
processes
such
as
growth,
differentiation,
and
development,
but
also
play
critical
roles
a
wide
spectrum
diseases,
including
cancer.
Dysregulated
ncRNA
expression
is
found
to
affect
initiation,
progression,
therapy
resistance,
through
transcriptional,
post-transcriptional,
or
epigenetic
cell.
In
this
review,
we
focus
recent
development
advances
are
pertinent
their
role
glioma
tumorigenesis
response.
Gliomas
common,
most
aggressive
type
primary
tumors,
which
account
for
~30%
central
nervous
system
(CNS)
tumors.
Of
these,
glioblastoma
(GBM),
grade
IV
lethal
brain
Only
5%
GBM
patients
survive
beyond
five
years
upon
diagnosis.
Hence,
deeper
understanding
cellular
transcriptome
might
help
identify
biomarkers
therapeutic
agents
better
treatment
glioma.
Here,
delve
into
functional
microRNA
(miRNA),
long
RNA
(lncRNA),
circular
(circRNA)
tumorigenesis,
discuss
extracellular
counterparts,
highlight
potential
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: May 10, 2022
Glioma
is
a
brain
tumor
that
arises
in
the
central
nervous
system
and
categorized
according
to
histology
molecular
genetic
characteristics.
Long
non-coding
RNAs
(lncRNAs)
are
longer
than
200
nucleotides
length.
They
have
been
reported
influence
significant
events
such
as
carcinogenesis,
progression,
increased
treatment
resistance
on
glioma
cells.
promote
cell
proliferation,
migration,
epithelial-to-mesenchymal
transition
invasion
Various
advancements
transcriptomic
profiling
studies
enabled
identification
of
immune-related
long
immune
cell-specific
gene
expression
regulators
mediates
both
stimulatory
suppressive
responses,
implying
lncRNAs
potential
candidates
for
improving
immunotherapy
efficacy
against
tumors
due
lack
different
diagnostic
treatments
glioma,
be
used
future
diagnostic,
prognostic
biomarker
tools
glioma.
This
review’s
primary
purpose
concentrate
role
early
identification,
treatment,
immunotherapy.
IBRO Neuroscience Reports,
Journal Year:
2025,
Volume and Issue:
18, P. 323 - 337
Published: Feb. 6, 2025
Non-coding
accounts
for
98
%-99
%
of
the
human
genome
and
performs
many
essential
regulatory
functions
in
eukaryotes,
involved
cancer
development
development.
RNAs
are
abundantly
enriched
exosomes,
which
play
a
biological
role
as
vectors.
Some
biofunctional
non-coding
specifically
designed
exosomes
treatment
cancers
such
glioma.
Glioma
is
one
most
common
primary
tumors
within
skull
has
varying
degrees
malignancy
histologic
subtypes
grades
I-IV.
Gliomas
characterized
by
high
an
abundant
blood
supply
due
to
rapid
cell
proliferation
vascularization,
often
with
poor
prognosis.
Exosomal
can
be
tumorigenesis
process
glioma
from
multiple
directions,
angiogenesis,
tumor
proliferation,
metastatic
invasion,
immune
evasion,
apoptosis,
autophagy.
Therefore,
suitable
markers
or
therapeutic
targets
early
diagnosis
diseases
predicting
prognosis
variety
diseases.
Regulating
exosome
production
level
exosomal
RNA
expression
may
new
approach
prevent
eliminate
In
this
review,
we
review
origin
characteristics
RNAs,
introduce
functional
studies
their
potential
clinical
applications,
order
broaden
ideas
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(2), P. 233 - 233
Published: Feb. 8, 2025
Background/Objectives:
Glioblastoma
multiforme
(GBM),
an
aggressive
and
deadly
brain
tumour,
presents
significant
challenges
in
achieving
effective
treatment
due
to
its
resistance
current
therapies
poor
prognosis.
This
study
aimed
synthesise
evaluate
23
novel
analogues
of
3,4-dihydroquinolin-2(1H)-one,
designed
enhance
druggability
solubility,
investigate
their
potential
as
VEGFR2
inhibitors
for
GBM
treatment.
Methods:
The
synthesised
compounds
were
analysed
using
silico
methods,
including
molecular
docking
dynamics
studies,
assess
interactions
with
key
residues
within
the
binding
pocket.
In
vitro
evaluations
performed
on
U87-MG
U138-MG
cell
lines
MTT
assays
determine
IC50
values
compounds.
Results:
Among
tested
compounds,
4u
(IC50
=
7.96
μM),
4t
10.48
4m
4.20
4q
8.00
μM)
demonstrated
antiproliferative
effects
against
both
lines.
These
exhibited
markedly
higher
efficacy
compared
temozolomide
(TMZ),
which
showed
92.90
μM
93.09
U138-MG,
respectively.
Molecular
studies
confirmed
strong
between
kinase,
supporting
substantial
anti-cancer
activity.
Conclusions:
highlights
promising
3,4-dihydroquinolin-2(1H)-one
analogues,
particularly
4m,
4q,
4t,
4u,
VEGFR2-targeting
therapeutic
agents
Further
detailed
research
is
warranted
validate
expand
upon
these
findings.
